Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study

[1]  Yuri Cho,et al.  Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus , 2021, Clinical and molecular hepatology.

[2]  J. H. Kim,et al.  Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop , 2020, Clinical and molecular hepatology.

[3]  Yasuhito Tanaka,et al.  Novel biomarkers for the management of chronic hepatitis B , 2020, Clinical and molecular hepatology.

[4]  M. N. Kim,et al.  High body mass index hinders fibrosis improvement in patients receiving long‐term tenofovir therapy in hepatitis B virus‐related cirrhosis , 2020, Journal of viral hepatitis.

[5]  Ah Ram Lee,et al.  Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. , 2019, Journal of hepatology.

[6]  P. Easterbrook,et al.  Access to treatment for hepatitis B virus infection—Worldwide, 2016 , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  P. Easterbrook,et al.  Access to Treatment for Hepatitis B Virus Infection — Worldwide, 2016 , 2018, MMWR. Morbidity and mortality weekly report.

[8]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[9]  S. Milani,et al.  Non‐invasive assessment of liver fibrosis in patients with HBV‐related chronic liver disease undergoing antiviral treatment: A preliminary study , 2017, European journal of pharmacology.

[10]  S. Ahn,et al.  Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis , 2017, The American Journal of Gastroenterology.

[11]  Sheng-Nan Lu,et al.  Three‐year efficacy and safety of tenofovir in nucleos(t)ide analog‐naïve and nucleos(t)ide analog‐experienced chronic hepatitis B patients , 2016, Journal of gastroenterology and hepatology.

[12]  G. Goh,et al.  Clinical applications, limitations and future role of transient elastography in the management of liver disease. , 2016, World journal of gastrointestinal pharmacology and therapeutics.

[13]  June-Sung Lee,et al.  Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients , 2015, Clinical and molecular hepatology.

[14]  M. N. Kim,et al.  Long‐term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[15]  J. Hwang,et al.  Effect of Virological Response to Entecavir on the Development of Hepatocellular Carcinoma in Hepatitis B Viral Cirrhotic Patients: Comparison Between Compensated and Decompensated Cirrhosis , 2014, The American Journal of Gastroenterology.

[16]  Sheng-Nan Lu,et al.  The Changes of Liver Stiffness and Its Associated Factors for Chronic Hepatitis B Patients with Entecavir Therapy , 2014, PloS one.

[17]  S. Park.  KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease , 2013, Clinical and molecular hepatology.

[18]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[19]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[20]  H. Yim,et al.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B , 2012, Clinical and molecular hepatology.

[21]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[22]  J. Hayashi,et al.  Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  E. Schiff,et al.  Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  E. Schiff,et al.  Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B , 2010, Hepatology.

[25]  M. Yuen,et al.  Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B , 2010, Hepatology international.

[26]  S. Paggi,et al.  Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B , 2010, European journal of gastroenterology & hepatology.

[27]  Pierre Bedossa,et al.  Non‐invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[28]  P. Marcellin,et al.  Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B , 2008, Hepatology.

[29]  M. Ziol,et al.  Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC , 2006, Hepatology.

[30]  M. Ziol,et al.  Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients , 2006, Journal of acquired immune deficiency syndromes.

[31]  Christos Christidis,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.

[32]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[33]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[34]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[35]  J. Kao,et al.  Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection , 2021, Hepatitis B Virus and Liver Disease.

[36]  Fabrice Carrat,et al.  Liver biopsy: the best, not the gold standard. , 2009, Journal of hepatology.

[37]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[38]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.